SOD2 Activity Analysis for L-Asparaginase Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments with L-asparaginase are ineffective for certain cancer types, particularly acute lymphoblastic leukemia (ALL) due to resistance developed by cancer cells, necessitating a method to predict and overcome this resistance.
Innovation Solution
An analytical method to determine the activity levels of superoxide dismutase (SOD2) and ubiquitin-protein ligases (UBR1 and UBR2) in cancer cells, using inhibitors to enhance sensitivity to L-asparaginase treatment by inhibiting protein degradation pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-asparaginase is used to treat cancer cells, then serum asparagine is depleted and therapeutic effect is achieved, but cancer cells develop resistance through upregulation of asparagine synthesis enzymes
Solution Approach 1:
The patent applies preliminary action by measuring SOD2 activity levels before initiating L-asparaginase treatment to predict which cancer cells will respond therapeutically. This pre-screening approach identifies susceptible cells before treatment begins, preventing waste of therapy on resistant cells and enabling early intervention with alternative strategies for resistant cases.
Solution Approach 2:
The patent implements feedback by using the measured SOD2 activity levels to guide treatment decisions. The biological marker provides continuous information about cancer cell susceptibility, allowing clinicians to adjust treatment plans based on the actual biological state of the patient's cells rather than following a fixed protocol.
2Measurement precision
If SOD2 activity is high in cancer cells, then resistance to L-asparaginase develops, but measuring SOD2 levels enables prediction and stratification of patients
Solution Approach 1:
The patent replaces complex functional assays with a simpler biochemical measurement approach. Instead of measuring the complex enzymatic activity of asparagine synthesis pathways directly, the invention uses SOD2 activity measurement as a surrogate marker, substituting a straightforward biochemical assay for a complex cellular functional test.
3Productivity
If L-asparaginase treatment is administered, then asparagine depletion occurs, but additional therapeutical agents are needed to overcome resistance in SOD2-high cancer cells
Solution Approach 1:
The patent applies local quality by tailoring the treatment approach to the specific characteristics of individual cancer cells. Rather than applying a uniform treatment protocol to all patients, the invention customizes therapy based on measured SOD2 activity levels, providing L-asparaginase monotherapy for SOD2-low cells and combination therapy for SOD2-high cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively predicts cancer cell sensitivity to L-asparaginase, increasing treatment efficacy by selecting appropriate therapeutic agents and enhancing sensitivity through targeted inhibition of SOD2 and UBR proteins, thereby overcoming resistance.
Implementation Method 1
The therapeutic effect of administration of L-asparaginase against cancer cells is seen in the depletion of serum asparagine by enzymatic conversion to aspartate.
Implementation Method 2
determining the level of activity of superoxide dismutase (SOD2)
Data Source
Figure 1A~1C
Figure 2A~2F
Figure 3A~3D
AI summary
The invention provides an analytical method for detecting the level of activity of superoxide dismutase (SOD2, e.g. UniProtKB P04179 (SODM_HUMAN) and/or of UBR1 and/or of UBR2 in a sample originating from a patient for determining the sensitivity for, or resistance against, tumour treatment with L-asparaginase.